Anacetrapib
Drugsingle dose administration of anacetrapib (MK0859) 100 mg oral tablet
NCT Number: NCT01114490
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Time frame: through 168 hours post dose
Time frame: through 14 days post dose
Merck Sharp & Dohme LLC
Industry
A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT07691268
Dyslipidemia, Dyslipidemias
Seoul, Gwanak-gu 08779, South Korea
View Trial DetailsNCT07627555
Cardiovascular Diseases, Dyslipidemia
Lahore, Pakistan
View Trial DetailsNCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial Details